Literature DB >> 1427402

Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma.

L E Puls1, D E Powell, P D DePriest, H H Gallion, J E Hunter, R J Kryscio, J R van Nagell.   

Abstract

The slides of all patients with ovarian cystadenocarcinoma treated at the University of Kentucky Medical Center from 1966-1990 were reviewed. Fifty-four serous tumors and 42 mucinous neoplasms were identified for further study. Benign epithelium adjacent to an area of borderline or malignant epithelium was observed in 74 tumors (79%) and a site of epithelial transition was noted in 38 cases (40%). The presence of associated benign epithelium was more common in borderline or well-differentiated lesions and in patients with early-stage disease. These findings are consistent with epidemiologic and molecular genetic data and suggest that certain benign serous or mucinous ovarian tumors have the potential for malignant transformation. Removal of these tumors, particularly in postmenopausal women, should result in a subsequent reduction in the frequency of ovarian cancer.

Entities:  

Mesh:

Year:  1992        PMID: 1427402     DOI: 10.1016/0090-8258(92)90075-t

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider.

Authors:  Haim A Abenhaim; Linda Titus-Ernstoff; Daniel W Cramer
Journal:  CMAJ       Date:  2007-03-27       Impact factor: 8.262

2.  Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity.

Authors:  Kathy Q Cai; Hong Wu; Andres J Klein-Szanto; Xiang-Xi Xu
Journal:  Gynecol Oncol       Date:  2009-04-16       Impact factor: 5.482

3.  Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.

Authors:  Linda E Kelemen; Marc T Goodman; Valerie McGuire; Mary Anne Rossing; Penelope M Webb; Martin Köbel; Hoda Anton-Culver; Jonathan Beesley; Andrew Berchuck; Sony Brar; Michael E Carney; Jenny Chang-Claude; Georgia Chenevix-Trench; Daniel W Cramer; Julie M Cunningham; Richard A Dicioccio; Jennifer A Doherty; Douglas F Easton; Zachary S Fredericksen; Brooke L Fridley; Margaret A Gates; Simon A Gayther; Aleksandra Gentry-Maharaj; Estrid Høgdall; Susanne Krüger Kjaer; Galina Lurie; Usha Menon; Patricia G Moorman; Kirsten Moysich; Roberta B Ness; Rachel T Palmieri; Celeste L Pearce; Paul D P Pharoah; Susan J Ramus; Honglin Song; Daniel O Stram; Shelley S Tworoger; David Van Den Berg; Robert A Vierkant; Shan Wang-Gohrke; Alice S Whittemore; Lynne R Wilkens; Anna H Wu; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-06-22       Impact factor: 4.254

4.  beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.

Authors:  C Gamallo; J Palacios; G Moreno; J Calvo de Mora; A Suárez; A Armas
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

5.  Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease.

Authors:  K Shigemasa; H Tanimoto; K Sakata; N Nagai; T H Parmley; K Ohama; T J O'Brien
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

6.  Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status.

Authors:  M Koshiyama; I Konishi; M Mandai; T Komatsu; S Yamamoto; K Nanbu; T Mori
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Mitotic arrest deficiency 2 induces carcinogenesis in mucinous ovarian tumors.

Authors:  Yusuke Nakano; Toshiyuki Sumi; Masanari Morishita; Takeshi Fukuda; Hiroyuki Nobeyama; Hiroyuki Yoshida; Yoshinari Matsumoto; Tomoyo Yasui; Osamu Ishiko
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

8.  Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.

Authors:  Liangdan Tang; Junzheng Yang; Shu-Kay Ng; Noah Rodriguez; Pui-Wah Choi; Allison Vitonis; Kui Wang; Geoffrey J McLachlan; Robert J Caiazzo; Brian C-S Liu; William R Welch; Daniel W Cramer; Ross S Berkowitz; Shu-Wing Ng
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162

Review 9.  Early events in ovarian oncogenesis.

Authors:  Dusica Cvetkovic
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

10.  Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia.

Authors:  Kathy Qi Cai; Corrado Caslini; Callinice D Capo-chichi; Carolyn Slater; Elizabeth R Smith; Hong Wu; Andres J Klein-Szanto; Andrew K Godwin; Xiang-Xi Xu
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.